urea cycle disorder
Metabolic · 2017–2019
4decisions
2medicines
3carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| sodium phenylbutyrate Chronic treatment of patients with urea cycle disorders (UCD) as second-line therapy in those who have failed or are intolerant to sodium benzoate, or who… | Mar 2019 | Not recommended | input received Metabolic Dietary Disorders Association |
| sodium phenylbutyrate Treatment of patients with urea cycle disorders (UCDs) who have elevated ammonia levels not controlled with diet alone and other adjunct care alone,… | Mar 2018 | Not recommended | input received |
| arginine Dietary management of urea cycle disorders (UCD). | Nov 2017 | Not recommended | none received |
| sodium phenylbutyrate Treatment of patients with urea cycle disorders (UCD) and elevated plasma ammonia levels not controlled with diet alone and other adjunct care. | Nov 2017 | Recommended with restriction | input received Metabolic Dietary Disorders Association |
Who spoke
Metabolic Dietary Disorders Association
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.